Graves Ophthalmopathy Clinical Trial
— EX3DOfficial title:
Exophthalmometry With 3D Face Scanners
Verified date | January 2021 |
Source | University of Zurich |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study investigates diagnostic methods to measure eyeball protrusion with a smartphone face scanner compared to the traditional Hertel exophthalmometer. The study aims to validate a new reliable, fast and convenient smartphone app to measure the protrusion of the eyeball in different diseases such as Graves' disease, orbital tumors, orbital fractures or orbital inflammation, as well as other rare diseases.
Status | Recruiting |
Enrollment | 180 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 31, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Written informed consent - Able to cooperate with the study investigations (hearing, comprehension) - Exophthalmos (Grave's disease, orbital tumors, orbital inflammation, orbital fractures, rare causes (congenital, e.g. microphthalmos) - health controls Exclusion Criteria: - Unable to sign informed consent - Unable to cooperate with the examinations (hearing loss, neurological deficits) |
Country | Name | City | State |
---|---|---|---|
Switzerland | Ophthalmology Department, University Hospital Zurich | Zurich |
Lead Sponsor | Collaborator |
---|---|
University of Zurich |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Accuracy of the smartphone face scanner | Accuracy of iPhone exophthalmos measurements (measured in mm for each eye) compared to measure with 3D face scanner and Hertel Exophthalmometer | On average 2 weeks | |
Primary | Test-retest-reliability of the smartphone face scanner | Repeated measures (measured in mm for each eye) of the same subjects with iPhone 11, Hertel Exophthalmometer and 3D face scanner | On average 2 weeks | |
Primary | Inter-operator reliability of the smartphone face scanner | Measurement (measured in mm for each eye) of the same patients by 3 different operators | On average 2 weeks | |
Primary | Smartphone face scanner measures before and after treatment with the smartphone face scanner | Measurements (measured in mm for each eye) with the smartphone face scanner before and after exophthalmos-changing treatment | On average 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05532072 -
Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.
|
Early Phase 1 | |
Completed |
NCT01727973 -
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
|
Phase 1/Phase 2 | |
Recruiting |
NCT06112340 -
A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
|
Phase 2/Phase 3 | |
Recruiting |
NCT05678374 -
Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease
|
||
Recruiting |
NCT03708627 -
Bimatoprost as a Treatment for Graves' Orbitopathy
|
Early Phase 1 | |
Not yet recruiting |
NCT06413043 -
Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy
|
N/A | |
Withdrawn |
NCT01379196 -
Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy
|
Phase 1/Phase 2 | |
Recruiting |
NCT06275373 -
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
|
||
Recruiting |
NCT06226545 -
A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
|
Phase 2 | |
Recruiting |
NCT05126147 -
Hydroxychloroquine in Mild Graves' Orbitopathy
|
Phase 4 | |
Recruiting |
NCT01999790 -
Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy
|
N/A | |
Recruiting |
NCT03066076 -
Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy
|
Phase 3 | |
Active, not recruiting |
NCT03122847 -
Glucocorticoids and Bone in Graves' Ophthalmopathy
|
||
Terminated |
NCT01893450 -
Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment
|
N/A | |
Completed |
NCT00348413 -
Thyroid Treatment Trial
|
N/A | |
Completed |
NCT03498417 -
Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy
|
||
Not yet recruiting |
NCT04598815 -
Sirolimus for Graves' Orbitopathy (GO)
|
Phase 2 | |
Terminated |
NCT01114503 -
A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease
|
Phase 2 | |
Completed |
NCT05775185 -
Therapeutic Efficacy of Orbital Radiotherapy in Patients With Graves' Orbitopathy
|
||
Completed |
NCT05793359 -
Comparison of the Effectiveness of Two Glucocorticoid Regimens for Treatment of Graves' Orbitopathy
|